


Remarks

If questions exist after entry of the foregoing, the Office is kindly requested to contact applicants' representative at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
Trask Britt, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: July 30, 2001

Enclosures: Copy of Notice to Comply with Requirements for Patent Applications Containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures
Paper copy of Sequence Listing
CRF copy of Sequence Listing
Statement under 37 C.F.R. §§ 1.821(g) and 1.825

N:\2183\3898\Amendment_625.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE\

IN THE SPECIFICATION:

Please amend page 11, line 7 so the paragraph entitled 6] appears as follows:

To prevent the peptide ac-CSDGAVQPDGGQPAVRNERATG-NH₂ (SEQ ID NO. 2) from dimerization by air oxidation, the free SH group was blocked. Peptide ac-CSDGAVQPDGGQPAVRNERATG-NH₂ (SEQ ID NO. 2) [ac-CSDGAVQPDGGQPAVRNERTAG-NH₂ (SEQ ID NO. 6)] (20 μmol) and iodoacetamide (100 μmol) was dissolved in 400 μl DMF and 600 μl 2% NH₄HCO₃ (pH 8.0). The pH was kept between 7.5 and 8.5, and if necessary corrected with extra NH₄HCO₃ (grains). The solution was stirred for some 1.5 to 2 hours at room temperature. Acetic acid (100%, 50 μl) was added to stop the reaction. An Ellmann test was used to analyse the result.